Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Net Cash Flow (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Net Cash Flow readings, the most recent being $23.8 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 202.49% to $23.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.7 million, a 56.78% increase, with the full-year FY2025 number at -$12.7 million, up 56.78% from a year prior.
  • Net Cash Flow hit $23.8 million in Q4 2025 for Amicus Therapeutics, down from $33.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $212.0 million in Q3 2021 to a low of -$146.9 million in Q4 2022.
  • Median Net Cash Flow over the past 5 years was $5.1 million (2023), compared with a mean of $2.8 million.
  • Biggest five-year swings in Net Cash Flow: surged 417.32% in 2023 and later plummeted 22769.93% in 2025.
  • Amicus Therapeutics' Net Cash Flow stood at -$138.7 million in 2021, then dropped by 5.92% to -$146.9 million in 2022, then soared by 91.64% to -$12.3 million in 2023, then crashed by 88.88% to -$23.2 million in 2024, then soared by 202.49% to $23.8 million in 2025.
  • The last three reported values for Net Cash Flow were $23.8 million (Q4 2025), $33.0 million (Q3 2025), and -$32.7 million (Q2 2025) per Business Quant data.